Page 3 - Biosensor Platform News Today

/PRNewswire/ -- OncoTEX Inc. (OncoTEX), a US oncology company and member of The iQ Group Global portfolio, is pleased to announce it has acquired a gold...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for...

/PRNewswire/ -- The iQ Group Global Ltd (NSX.IQG), on behalf of its subsidiary, Life Science Biosensor Diagnostics Pty Ltd (LSBD), is pleased to announce that...

IQX Limited (NSX:IQX) Portfolio Company Awarded $6.3M Federal Govt Grant    Portfolio Company Awarded $6.3M Federal Govt GrantSydney, July 9, 2021 AEST (ABN Newswire) - iQX Limited ( NSX:IQX), on behalf of Life Science Biosensor Diagnostics Pty Ltd (LSBD), in which IQX holds 19% equity position, that LSBDs subsidiary GBS today announced it has been awarded a AUD $6.3 million, Australian Federal Government scientific grant to create a pilot Biosensor manufacturing facility. GBS Inc ( NASDAQ...

IQX Limited (NSX:IQX) Progress of Clinical Programs    Progress of Clinical ProgramsSydney, April 29, 2021 AEST (ABN Newswire) - iQX Limited (iQX Ltd) ( NSX:IQX) would like to announce that Life Science Biosensor Diagnostics Pty Ltd (LSBD) in which iQX Ltd holds a 19% equity position, has received approval from the Harvard Longwood campus Institutional Review Board (IRB) to commence a clinical validation study to test patient samples from a COVID-19 repository. The study follows a partners...

NEW YORK, Dec. 28, 2020 -- GBS Inc. , a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point... | January 24, 2021

GBS Inc. Announces Pricing of Initial Public Offering Will Trade on the Nasdaq Global Market Under Ticker “GBS” NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) — GBS Inc. (the “Company”) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care, today announced the pricing of its initial public offering of 1,270,589 units at a public offering price of $17.00 per unit. Each unit...

UPDATE – GBS Inc. Announces Pricing of $21.6 Million Initial Public Offering Will Trade on the Nasdaq Global Market Under Ticker “GBS” NEW YORK, Dec. 23, 2020 (GLOBE NEWSWIRE) — GBS Inc. (the “Company”) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care, today announced the pricing of its initial public offering of 1,270,589 units at a public offering price of $...